Drug name | Drug sensitivity | Evidence |
17-AAG | High-risk group | Sauvageot et al. [33] |
AG-014699 (Rucaparib) | High-risk group | Zhang et al. [34] |
Bortezomib | High-risk group | Su et al. [35] |
Dasatinib | High-risk group | Alhalabi et al. [36] |
Lapatinib | High-risk group | Yu et al. [37] |
LY317615 | High-risk group | Graff et al. [38] |
MG-132 | High-risk group | Li et al. [39] |
OSI-930 | High-risk group | Yang et al. [40] |
Paclitaxel | High-risk group | Yang et al. [41] |
Pazopanib | High-risk group | Haraldsdottir et al. [42] |
PD-0332991 | High-risk group | Michaud et al. [43] |
Rapamycin | High-risk group | Le et al. [44] |
Ruxolitinib | High-risk group | Delen et al. [45] |
Temsirolimus | High-risk group | Kaley et al. [46] |
TGX221 | High-risk group | Yang et al. [47] |
Z-LLNle-CHO | High-risk group | Monticone et al. [48] |
BMS-754807 | Low-risk group | Fuentes-Baile et al. [49] |
FK866 | Low-risk group | Feng et al. [50] |
Salubrinal | Low-risk group | He et al. [51] |